Developed by using MonoSol Rx’s PharmFilm technology, Zuplenz is a film formulation that delivers either 4 or 8mgs of ondansetron.
Zuplenz helps in preventing postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.
MonoSol Rx chief technology officer and CEO Mark Schobel said Zuplenz provides patients suffering from nausea and vomiting as a result of chemotherapy or surgery with a minimally invasive and highly tolerable drug delivery form.
"We look forward to maximizing this potential with a pharmaceutical partner that can effectively detail to physicians in the sizable US market," Schobel said.